Saliva and tooth changes in adults starting semaglutide or tirzepatide for obesity
Follows saliva and teeth in adults starting semaglutide or tirzepatide for obesity.
Plain-language title generated from the registry record
Registry title: Salivary Function and Dental Changes During GLP-1 Therapy
Key facts
- Where
- Bilecik, TürkiyeSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with obesity whose endocrinologist has decided to start semaglutide or tirzepatide. Saliva and teeth are checked before treatment and after 3 months.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Body mass index (BMI) of 27 kg/m² or higher, with an endocrinologist's decision to start semaglutide or tirzepatide for obesity
- Earlier treatment
- No earlier treatment with any GLP-1 receptor agonist
Main reasons for not taking part
- Head and neck radiotherapy in the past
- Sjögren syndrome or other disease affecting the salivary glands
- Chronic kidney disease
- Pregnancy or breastfeeding
- Eating disorder with repeated self-induced vomiting, such as bulimia nervosa
Read by machine on 12 November 2026.
Where in Türkiye
- Department of Periodontology, Bilecik Seyh Edebali University Faculty of DentistryBilecik, TürkiyeContact: Yasemin B. ÖNDER, DDS,pHDNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Bilecik Seyh Edebali Universitesi
- Trial code
- NCT07720466
- Record updated
- 22 July 2026
- Original description
People who use glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide and tirzepatide, may experience changes in their oral health. Some people report dry mouth, changes in saliva, and increased wear of their teeth after starting these medicines. However, little is known about whether these medicines affect saliva and dental hard tissues.Read full original descriptionShow less
Prospective Evaluation of Salivary Calcium Levels, Salivary Function, and Dental Hard Tissue Changes in Patients Receiving GLP-1 Receptor Agonist Therapy
People who use glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide and tirzepatide, may experience changes in their oral health. Some people report dry mouth, changes in saliva, and increased wear of their teeth after starting these medicines. However, little is known about whether these medicines affect saliva and dental hard tissues.
The purpose of this study is to evaluate changes in salivary calcium levels, salivary function, and dental hard tissues in adults who begin treatment with semaglutide or tirzepatide for obesity.
Approximately 40 participants will be enrolled before starting GLP-1 receptor agonist therapy. Oral examinations, standardized intraoral photographs, saliva samples, and body weight measurements will be obtained before treatment and again after three months. Saliva samples will be analyzed for calcium concentration, pH, and salivary flow rate. Dental hard tissue changes will be assessed using the Basic Erosive Wear Examination (BEWE) index.
The findings from this study may improve understanding of the effects of GLP-1 receptor agonists on oral health and help healthcare professionals identify and prevent possible dental complications during treatment.
Inclusion: Adults aged 18 years or older; Body mass index (BMI) ≥27 kg/m²; Clinical decision by an endocrinologist to initiate semaglutide or tirzepatide therapy for obesity management; No previous treatment with GLP-1 receptor agonists; Willingness to participate and ability to provide written informed consent; Willingness to attend both the baseline and 3-month follow-up visits.
Exclusion: Previous use of any GLP-1 receptor agonist; Use of medications known to markedly affect salivary secretion; History of head and neck radiotherapy; Sjögren syndrome or other systemic diseases affecting salivary gland function; Chronic kidney disease; History of eating disorders associated with recurrent self-induced vomiting (e.g., bulimia nervosa); Medical conditions causing persistent vomiting or severe gastroesophageal disease unrelated to GLP-1 therapy; Pregnancy or breastfeeding; Active orthodontic treatment; Severe dental erosion requiring restorative treatment at baseline; Edentulism or the absence of anterior teeth required for dental hard tissue assessment; Inability or unwillingness to comply with the study protocol or attend the 3-month follow-up visit.